Psychedelic therapy gets a major boost from the US Government

On April 18, an Executive Order was signed to accelerate the development of, and access to, psychedelic therapies for serious mental illness. The order prioritizes faster FDA review through priority vouchers, expands “Right to Try” access to investigational treatments, increases federal research funding, and promotes collaboration across agencies and the private sector, with a particular focus on providing these therapies for our veterans who suffer from PTSD.

This marks a major step forward for the psychedelics industry, aiming to remove regulatory barriers, expedite clinical trials, and enable faster rescheduling of approved therapies. Clearly this bodes well for psychedelics, positioning them as a promising, more widely available treatment option. Broader patient safety monitoring and continued maturity in psychedelic trials are important when psychedelics are used for PTSD treatment. Initial results are promising, so this boost of focus, speed, and attention will be helpful to the industry, and most importantly, to the patients who need help with their mental illnesses.